FDA approves Enzon's IND for cancer therapy

The FDA has approved Enzon Pharmaceuticals' IND for its HIF-1 alpha antagonist for various cancer types, including common solid tumors. The company plans to initiate a Phase I trial in the first half of 2007. "This marks an important milestone for Enzon as we continue to focus our efforts on important oncology therapies," said Jeffrey Buchalter, chairman and chief executive officer of the company. "The continued advancement of the HIF-1 alpha program demonstrates our commitment to developing a differentiated cancer portfolio."

- check out the press release for more

ALSO: Denmark's Santaris Pharma won a $5 million milestone from the acceptance of the IND. Release

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.